ILMN Illumina, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
ILMN Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Diagnostics & Research
Current Price
Live
$141.65
Analyst Target
$131.47
-7.2%
Downside
52W High
$151.34
52W Low
$68.7
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 17, 2026
Market cap
$21.77B
P/E
31.76
ROE
31.2%
Profit margin
16.4%
Debt/Equity
1.08
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
68%
Analysis Accuracy
ILMN's deterministic health score is weak with a Piotroski F-Score of 4/9, indicating borderline financial stability. Despite strong profitability metrics like a 31.2% ROE and 68.38% gross margin, the company faces significant headwinds from negative earnings growth (-77.8% YoY) and a high valuation (P/E of 31.76 vs. sector average of 256.48, though skewed). The stock trades well above the Graham Number of $39.52 and intrinsic value of $31.22, suggesting substantial premium pricing, while insider selling and weak technical trend (10/100) add caution. However, recent earnings surprises and improving quarterly EPS trends provide some optimism for recovery.
Key Strengths
High return on equity (31.20%) indicating efficient use of shareholder capital
Strong gross margin (68.38%) reflecting pricing power and cost control
Consistently beating earnings estimates in recent quarters (3 of last 4)
Significant year-over-year EPS growth rebound (+17.5%) despite prior-year drag
Low debt relative to equity compared to sector average (Debt/Equity 1.08 vs. sector 0.92)
Key Risks
Weak Piotroski F-Score (4/9) signaling potential financial instability
Sharp decline in earnings growth (YoY: -77.8%, Q/Q: -78.7%) indicating profit collapse
Stock trades at a large premium to conservative fair value (Current: $141.65 vs. Graham: $39.52)
Insider selling activity over last 6 months suggesting lack of confidence
Very weak technical trend (10/100) and bearish price momentum despite short-term bounce
AI Fair Value Estimate
Based on comprehensive analysis
$45.0
-68.2% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
36
Weak
30
45
55
40
10
AI Verdict
Neutral with upside risk if growth stabilizes
Key drivers: High profitability metrics, Poor earnings growth trajectory, Rich valuation multiples, Weak technical and insider signals, Improving recent earnings surprises
Confidence
70%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Sector-relative P/E is reasonable (31.76 vs. skewed average of 256.48)
Watchpoints
- Price/Book of 9.10 is very high
- Current price ($141.65) is 3.6x Graham Number ($39.52)
- No PEG ratio due to unreliable growth forecast
Future
45/100
Ref Growth rates
Positives
- Recent Q/Q EPS growth of +12.6% shows improvement
- Year-over-year EPS growth rebounding to +17.5%
Watchpoints
- Revenue growth nearly flat (0.40% YoY)
- Earnings growth down sharply (-77.8% YoY)
Past
55/100
Ref Historical trends
Positives
- History of large earnings surprises (e.g., +135.1%, +1326% in 2023)
- Long-term track record of beating estimates in 19 of 25 quarters
Watchpoints
- Recent earnings miss in Q2 2024 (-60% surprise)
- Volatility in earnings performance over past two years
Health
40/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.43 and quick ratio of 1.03 indicate short-term liquidity
- Debt/Equity of 1.08 is manageable
Watchpoints
- Piotroski F-Score of 4/9 indicates weak financial health
- Altman Z-Score unavailable, limiting distress risk assessment
Dividend
10/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout history
- Dividend strength score of 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$141.65
Analyst Target
$131.47
Upside/Downside
-7.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ILMN and closest competitors.
Updated 2026-01-16
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ILMN
Illumina, Inc.
Primary
|
-62.7% | -29.5% | +3.1% | +47.3% | +9.3% | +0.4% |
|
CNC
Centene Corporation
Peer
|
-27.1% | -40.4% | -27.2% | +63.7% | +17.7% | -1.9% |
|
INCY
Incyte Corporation
Peer
|
+13.0% | +30.7% | +46.6% | +56.5% | +8.8% | -0.6% |
|
DXCM
DexCom, Inc.
Peer
|
-31.7% | -50.1% | -22.2% | -32.1% | -11.2% | +5.6% |
|
BIIB
Biogen Inc.
Peer
|
-37.7% | -41.2% | +19.4% | +30.5% | -2.7% | +4.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
31.76
Forward P/E
27.96
PEG Ratio
N/A
P/B Ratio
9.1
P/S Ratio
5.08
EV/Revenue
5.35
EV/EBITDA
19.66
Market Cap
$21.77B
Profitability
Profit margins and return metrics
Profit Margin
16.39%
Operating Margin
21.4%
Gross Margin
68.38%
ROE
31.2%
ROA
9.15%
Growth
Revenue and earnings growth rates
Revenue Growth
+0.4%
Earnings Growth
-77.8%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-78.7%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.08
Moderate
Current Ratio
1.43
Good
Quick Ratio
1.03
Good
Cash/Share
$8.36
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-05
$N/A
2025-10-30
$1.34
+14.7% surprise
2025-07-31
$1.19
+17.7% surprise
2025-05-08
$0.97
+3.3% surprise
Healthcare Sector Comparison
Comparing ILMN against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
P/E Ratio
31.76
This Stock
vs
164.56
Sector Avg
-80.7%
(Discount)
Return on Equity (ROE)
31.2%
This Stock
vs
-52.77%
Sector Avg
-159.1%
(Below Avg)
Profit Margin
16.39%
This Stock
vs
-20.78%
Sector Avg
-178.9%
(Weaker)
Debt to Equity
1.08
This Stock
vs
6.16
Sector Avg
-82.4%
(Less Debt)
Revenue Growth
0.4%
This Stock
vs
137.39%
Sector Avg
-99.7%
(Slower)
Current Ratio
1.43
This Stock
vs
3.36
Sector Avg
-57.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ILMN
Illumina, Inc.
|
NEUTRAL | $21.77B | 31.76 | 31.2% | 16.4% | $141.65 | |
|
CNC
Centene Corporation
|
BEARISH | $22.49B | - | -21.9% | -3.2% | $45.75 | |
|
INCY
Incyte Corporation
|
NEUTRAL | $20.85B | 18.0 | 30.4% | 24.7% | $106.21 | |
|
DXCM
DexCom, Inc.
|
BULLISH | $23.29B | 32.26 | 30.6% | 16.0% | $58.06 | |
|
BIIB
Biogen Inc.
|
NEUTRAL | $25.17B | 15.84 | 9.3% | 16.0% | $171.59 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-31 | ULLEM SCOTT B | Director | Stock Award | 212 | $24,938 |
| 2025-12-12 | DAVIES SCOTT M | Officer | Sale | 323 | $43,957 |
| 2025-12-08 | WEDEL CHRISTENSEN JAKOB | Officer | Sale | 549 | $70,969 |
| 2025-11-03 | GOTTLIEB SCOTT | Director | Purchase | 500 | $61,065 |
| 2025-09-30 | ULLEM SCOTT B | Director | Stock Award | 252 | $24,990 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
17 analysts
TD Cowen
2026-01-07
Hold
Hold
Guggenheim
2026-01-05
Buy
Buy
Canaccord Genuity
2025-12-22
Hold
Hold
Barclays
2025-12-15
Underweight
Underweight
JP Morgan
2025-12-15
Neutral
Neutral
Barclays
2025-10-31
Underweight
Underweight
Canaccord Genuity
2025-10-31
Hold
Hold
JP Morgan
2025-10-31
Neutral
Neutral
TD Cowen
2025-10-31
Hold
Hold
UBS
2025-10-31
Neutral
Neutral
Past News Coverage
Recent headlines mentioning ILMN from our newsroom.
Newest → oldest
No matching news yet.